BiotechTube

lixivaptan + placebo

Phase 3Completed
0 views this week 0 watching💤 Quiet
Interest: 37/100
37
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hyponatremia With Normal Extracellular Fluid Volume

Conditions

Hyponatremia With Normal Extracellular Fluid Volume

Trial Timeline

Apr 1, 2008 → —

NCT ID
NCT00660959

About lixivaptan + placebo

lixivaptan + placebo is a phase 3 stage product being developed by Biogen for Hyponatremia With Normal Extracellular Fluid Volume. The current trial status is completed. This product is registered under clinical trial identifier NCT00660959. Target conditions include Hyponatremia With Normal Extracellular Fluid Volume.

What happened to similar drugs?

1 of 7 similar drugs in Hyponatremia With Normal Extracellular Fluid Volume were approved

Approved (1) Terminated (4) Active (3)
🔄YM087Astellas PharmaPhase 3
✅ConivaptanAstellas PharmaApproved
❌ConivaptanAstellas PharmaPhase 3
❌Satavaptan + placeboSanofiPhase 3
🔄lixivaptan + PlaceboBiogenPhase 3
❌LixivaptanBiogenPhase 3
🔄Lixivaptan + PlaceboBiogenPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
12
Novelty
0
Community
0

Clinical Trials (3)

NCT IDPhaseStatus
NCT00876798Phase 3Completed
NCT00660959Phase 3Completed
NCT00578695Phase 3Completed

Competing Products

9 competing products in Hyponatremia With Normal Extracellular Fluid Volume

See all competitors
ProductCompanyStageHype Score
YM087Astellas PharmaPhase 3
40
ConivaptanAstellas PharmaApproved
35
ConivaptanAstellas PharmaPhase 3
32
Tolvaptan + PlaceboJiangsu Hengrui MedicinePhase 2/3
34
Satavaptan + placeboSanofiPhase 3
32
lixivaptan + PlaceboBiogenPhase 3
37
LixivaptanBiogenPhase 3
29
Lixivaptan + PlaceboBiogenPhase 3
37
PEG-SD + PEG-ELSBausch HealthPre-clinical
20